FindTrial
Sign In

fluoruracil

DRUG4 trials

Sponsors

Gruppo Oncologico del Nord-Ovest, N.N. Petrov National Medical Research Center of Oncology, Gruppo Oncologico Italiano di Ricerca Clinica, Canadian Cancer Trials Group

Conditions

Breast CancerColorectal CancerMetastatic Colorectal CancerRectal Cancer

Phase 2

Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer.
NCT02506777
N.N. Petrov National Medical Research Center of OncologyBreast Cancer
Start: 2015-07-31End: 2020-08-31Target: 96Updated: 2019-09-04
Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients
CompletedNCT04072198
Gruppo Oncologico Italiano di Ricerca ClinicaColorectal Cancer
Start: 2019-09-26End: 2024-10-30Updated: 2025-03-13

Phase 3

Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC
NCT02339116
Gruppo Oncologico del Nord-OvestMetastatic Colorectal Cancer
Start: 2015-02-26End: 2021-02-28Target: 654Updated: 2020-02-05
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
RecruitingNCT06205485
Canadian Cancer Trials GroupRectal Cancer
Start: 2024-06-26End: 2030-06-30Target: 250Updated: 2026-07-14

Related Papers

Development of a computational histology artificial intelligence (CHAI)–powered predictive biomarker for first-line chemotherapy intensification in metastatic colorectal cancer (mCRC) and validation in prospective randomized phase III trials (RCT).
Journal of Clinical Oncology2026-05-27
First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial
Nature Communications2026-03-25
Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer.
2025-11-18
FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials.
2025-08-15
Causal analyses of the impact of comorbid conditions and concomitant medications on response to neoadjuvant chemotherapy in breast cancer: analysis of a multicenter prospective cohort study (CANTO).
2025-05-15
The NEO-RT trial: A phase 3 randomized trial of neoadjuvant chemotherapy, excision and observation versus chemoradiotherapy for early rectal cancer, CCTG CO.32.
Journal of Clinical Oncology2024-06-013 citations
FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable liver-only, right-sided and/or <i>RAS</i> or <i>BRAF</i> mutated (mut) metastatic colorectal cancer (mCRC): An individual patient data-based pooled analysis of randomized trials.
Journal of Clinical Oncology2024-06-01
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study
Future Oncology2023-07-015 citations
Phase II study of nivolumab in combination with FOLFOXIRI/bevacizumab as first-line treatment in patients with advanced colorectal cancer RAS/BRAF mutated (mut): NIVACOR trial (GOIRC-03-2018).
Journal of Clinical Oncology2022-06-0120 citations
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies.
2022-05-1714 citations
FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial
Frontiers in Oncology2021-12-1418 citations
Preliminary safety analysis of phase II open-label NIVACOR trial (GOIRC-03-2018) in patients with advanced colorectal cancer RAS or BRAF mutated.
Journal of Clinical Oncology2021-01-208 citations
Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
2020-08-3123 citations
Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer
Journal of Clinical Oncology2020-08-20230 citations
FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable metastatic colorectal cancer (mCRC): A meta-analysis of individual patient data (IPD) from five randomized trials.
Journal of Clinical Oncology2020-05-2012 citations
Consensus molecular subtypes and CRCassigner classifications in metastatic colorectal cancer (mCRC): Prognostic and predictive impact in the TRIBE2 study.
Journal of Clinical Oncology2020-05-208 citations
NIVACOR: Phase II study of nivolumab in combination with FOLFOXIRI/bevacizumab in first-line chemotherapy for advanced colorectal cancer RASm/BRAFm patients.
Journal of Clinical Oncology2020-05-206 citations
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
2020-03-09235 citations
Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC.
Journal of Clinical Oncology2019-05-2022 citations
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.
2017-06-0924 citations

1 more papers not shown